How the European in vitro diagnostic regulation could negatively impact the European response to the next pandemic : an urgent call for action before May 2022
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 27(2021), 8 vom: 21. Aug., Seite 1074-1075 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vermeersch, Pieter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 testing |
|---|
| Anmerkungen: |
Date Completed 19.08.2021 Date Revised 02.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2021.05.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325311366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325311366 | ||
| 003 | DE-627 | ||
| 005 | 20231225192155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2021.05.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325311366 | ||
| 035 | |a (NLM)33979703 | ||
| 035 | |a (PII)S1198-743X(21)00230-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vermeersch, Pieter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How the European in vitro diagnostic regulation could negatively impact the European response to the next pandemic |b an urgent call for action before May 2022 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2021 | ||
| 500 | |a Date Revised 02.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 testing | |
| 650 | 4 | |a Diagnostic test approval | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a IVD | |
| 650 | 4 | |a IVDR | |
| 650 | 4 | |a In vitro diagnostic regulation | |
| 650 | 4 | |a Lab-developed test | |
| 650 | 4 | |a Medical device legislation | |
| 700 | 1 | |a André, Emmanuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 27(2021), 8 vom: 21. Aug., Seite 1074-1075 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:8 |g day:21 |g month:08 |g pages:1074-1075 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2021.05.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 8 |b 21 |c 08 |h 1074-1075 | ||